Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Leveljump HealthcareJMPHF Debt-to-EBITDA is 11.50 as of Mar. 2026, which is 105% above its 10-year median of 5.61. The stock has 1 warning sign investors should review. Among 112 Medical Diagnostics & Research companies, Leveljump Healthcare ranks worse than 81.25% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Leveljump Healthcare's Debt-to-EBITDA or its related term are showing as below:
JMPHF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.74 Med: 5.61 Max: 7.87
Current: 7.78
During the past 7 years, the highest Debt-to-EBITDA Ratio of Leveljump Healthcare was 7.87. The lowest was -6.74. And the median was 5.61.
JMPHF's Debt-to-EBITDA is ranked worse than 81.25% of 112
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.31
vs JMPHF: 7.78
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Leveljump Healthcare Debt-to-EBITDA Related Terms
Leveljump Healthcare Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Leveljump Healthcare's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JMPHF vs TMO, DHR, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Leveljump Healthcare's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Leveljump Healthcare Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Leveljump Healthcare's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Leveljump Healthcare's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Leveljump Healthcare (JMPHF) has a Debt-to-EBITDA of 11.50 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Leveljump Healthcare. This is 105% above median its historical median of 5.61. According to the industry distribution chart, Leveljump Healthcare ranks #91 out of 112 companies in the Medical Diagnostics & Research industry, placing it in the top 81.2%.
Is Leveljump Healthcare's Debt-to-EBITDA too high?
Leveljump Healthcare's current Debt-to-EBITDA of 11.50 is 105% above median its 10-year median of 5.61. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.31. Leveljump Healthcare's value of 11.50 is 397.8% above this industry median. Based on the distribution chart, Leveljump Healthcare ranks #91 out of 112 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Leveljump Healthcare's Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Leveljump Healthcare ranks #91 out of 112 companies for Debt-to-EBITDA. This places Leveljump Healthcare in the lower half of its industry. The industry median Debt-to-EBITDA is 2.31. Leveljump Healthcare's value of 11.50 is 397.8% above this benchmark. While the company's 10-year median is 5.61 vs. the industry median of 2.31, Leveljump Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.31, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Leveljump Healthcare's current Debt-to-EBITDA of 11.50 is 397.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Leveljump Healthcare. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Leveljump Healthcare's current Debt-to-EBITDA is 11.50, which is 105% above median its own 10-year median of 5.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Leveljump Healthcare stock overvalued right now?
Leveljump Healthcare (JMPHF) has a current Debt-to-EBITDA of 11.50. The stock's GF Value™ is $0.05, compared to a current price of $0.04 — trading 14.5% below its estimated fair value. The current Debt-to-EBITDA is 11.50, which is 105% above median its 10-year median of 5.61 and 397.8% above the Medical Diagnostics & Research industry median of 2.31. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Leveljump Healthcare (JMPHF), the current Debt-to-EBITDA is 11.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Leveljump Healthcare Corp is engaged in providing radiology services both by providing direct patient images and by providing Teleradiology services, which is the process of providing remote off-site reading of radiology scans such as CT, MRI, and X-ray. Its teleradiology services allow hospital staff to scan their emergency room patients, then page the company's radiologist on call, who can then remotely view, via a secured server, the images and diagnose the patient, and provide a report back to the hospital. Leveljump provides its direct-to-patient services at its Independent Healthcare Facilities (IHFs). The company operates as a single segment, with all of its core assets, intellectual property, and development work being conducted in Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JMPHF has been successfully added to your 
